Additionally, combination therapy with doxorubicin and IL-12 has been shown to shift receptor signaling in tumor infiltrating CD8+ T cells toward immunostimulatory pathways while reducing Treg infiltration, thus enhancing local effector activity (64). The gene discussed is CD8A; the disease is neoplasm.